Risk of Subsequent Primary Cancer in Thyroid Cancer Survivors: A Nationwide Population-Based Study

Background: Despite obtaining a good prognosis and long life expectancy, survivors of thyroid cancer can nevertheless develop subsequent primary cancer (SPC). We investigated the risk and types of SPC in patients with thyroid cancer and compared them with subjects without thyroid cancer history (controls). Methods: We conducted a nationwide, population-based, retrospective cohort study based on the Korean National Health Insurance Database. A total of 432,654 patients diagnosed with thyroid cancer between 2004 and 2019 were 1:1 matched with controls for age, sex, income, and region of residence. The hazard ratios (HR) and 95% confidence intervals (CI) of SPC were estimated using Cox proportional hazard models. Results: In total, 78,584 (18.2%) patients with thyroid cancer and 49,979 (11.6%) controls were diagnosed with SPCs over a mean follow-up of 6.9 years. Patients with thyroid cancer had a higher risk of SPC at any site (adjusted HR, 1.62; 95% CI, 1.60–1.64) than the controls. The risk of SPCs was particularly high for patients diagnosed with thyroid cancer at a younger age (<40 years) and within 5 years. Conclusions: Medical caregivers should consider the long-term follow-up of patients with thyroid cancer and discuss the risk of SPC, especially if they complain of cancer-related symptoms.

[1]  K. Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019 , 2022, Cancer research and treatment.

[2]  Mijin Kim,et al.  Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study. , 2022, European journal of endocrinology.

[3]  Hun‐Sung Kim,et al.  Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research , 2021, Journal of lipid and atherosclerosis.

[4]  P. Piaggi,et al.  Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? , 2020, International journal of cancer.

[5]  S. Park,et al.  Incidence of Hypoparathyroidism After Thyroid Cancer Surgery in South Korea, 2007-2016. , 2019, JAMA.

[6]  S. Ezzat,et al.  A primer on the genetics of medullary thyroid cancer. , 2019, Current oncology.

[7]  M. Tucker,et al.  Risk of Second Primary Bone and Soft-Tissue Sarcomas Among Young Adulthood Cancer Survivors. , 2019, JNCI cancer spectrum.

[8]  C. Goldsmith,et al.  A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[9]  Ken R. Smith,et al.  Aging-Related Disease Risks among Young Thyroid Cancer Survivors , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[10]  E. Limbert,et al.  Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? , 2017, Thyroid : official journal of the American Thyroid Association.

[11]  L. Morris,et al.  Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. , 2015, Thyroid : official journal of the American Thyroid Association.

[12]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[13]  J. Chung,et al.  Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population‐based study in Korea , 2015, Cancer.

[14]  Shuangge Ma,et al.  The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. , 2013, Thyroid : official journal of the American Thyroid Association.

[15]  J. Tward,et al.  The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  E. Ron,et al.  Thyroid cancer and multiple primary tumors in the SEER cancer registries 1 , 2005, International journal of cancer.

[17]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[18]  P. Hall,et al.  Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.

[19]  K. Hemminki,et al.  Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. , 2004, IARC scientific publications.